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Chemotherapy alters the structure and function of hair
follicle melanocytes. Molecular mechanisms control-
ling melanocyte responses during chemotherapy-in-
duced hair loss, however, remain largely unknown.
Using immunohistology and multicolor confocal mi-
croscopy, we show here that cyclophosphamide admin-
istration to C57BL/6 mice alters the activity and fate of
hair follicle melanocytes. After 24^48 h, hair bulb mel-
anocytes expressing Fas undergo apoptosis.The number
of apoptotic follicular melanocytes is signi¢cantly
reduced (po0.01) in cyclophosphamide-treated Fas
knockout mice compared to wild-type controls, sug-
gesting that Fas signaling contributes to chemother-
apy-induced melanocyte death. After 3^5 d, surviving
hair bulb melanocytes express c-kit receptor, prolifer-
ate, and appear to migrate up the outer root sheath.Tyr-
osinase-positive and melanogenically active cells then
appear in the epidermis. By Western blotting and im-
munohistochemistry, expression levels of the c-kit li-
gand, stem cell factor, in skin and epidermis are
strongly increased after cyclophosphamide treatment.
Cyclophosphamide-induced migration of the hair folli-
cle melanocytes into epidermis is completely abrogated
by administration of c-kit neutralizing antibody. These
data suggest that chemotherapy induces a complex re-
sponse in the hair follicle melanocytes, which includes
apoptosis, proliferation, and migration. Pharmacologic
manipulation of Fas and c-kit signaling pathways might
be useful for the correction of skin hyperpigmentation
as a side-e¡ect of chemotherapy. Key words: cyclopho-
sphamide/DNA Damage/skin/pigmentation. J Invest Derma-
tol 120:27 ^35, 2003
T
hehair follicle (HF) represents a hair-shaft-producing
mini-organ that manifests during postnatal life cyclic
changes in its activity with periods of relative resting
(telogen), active growth and hair shaft production
(anagen), and apoptosis-driven involution (catagen)
(reviewed in Paus and Cotsarelis, 1999; Stenn and Paus, 2001).
Because of the rapid proliferation rate of hair matrix keratino-
cytes required for hair shaft production during anagen, the HF
represents a target for chemotherapeutic agents (reviewed in Cot-
sarelis, 1997; Paus and Cotsarelis, 1999; Cotsarelis and Millar, 2001;
Botchkarev, 2003). Anticancer drugs impair metabolic and mito-
tic processes in actively growing HFs, as well as stimulate prema-
ture apoptosis-driven HF regression (Paus et al, 1994; Cece et al,
1996; Lindner et al, 1997). Both processes result in hair loss (alope-
cia), a psychologically devastating side-e¡ect of cancer therapy
(reviewed in Bronner and Hood, 1983; Hubbard, 1985; Hussein,
1993).
Signi¢cant progress in understanding the pathobiology of che-
motherapy-induced hair loss was achieved using the C57BL/6
mouse model (Paus et al, 1994; 1996; Lindner et al, 1997). In this
model, HFs of postnatal mice are synchronized in anagen phase
by depilation, and a single intraperitoneal administration of 150
mg per kg cyclophosphamide (CYP) induces severe alopecia
strikingly reproducing the HF response seen in human CYP-in-
duced hair loss (Paus et al, 1994). Using this model, it was shown
that CYP upregulates ‘‘death’’ receptors [Fas/Apo-1, p55 kDa tu-
mor necrosis factor receptor (p55TNFR)] and the mitochondrial
pro-apoptotic protein Bax in the HF (Lindner et al, 1999).
Using the C57BL/6 mouse model for chemotherapy-induced
hair loss, we have recently demonstrated that p53 plays an essen-
tial role in mediating CYP-induced apoptosis in the HF (Botch-
karev et al, 2000a). We showed that CYP-treated HFs display a
strong upregulation of p53 in the proximal outer and inner root
sheaths and in the hair matrix. Furthermore, in contrast to wild-
type mice, p53-de¢cient mice show neither hair loss nor apopto-
sis in the follicular keratinocytes, and instead the HFs maintain
active proliferation after CYP treatment (Botchkarev et al, 2000a).
Chemotherapy can cause skin hyperpigmentation and is often
accompanied by altered color of regrown hair (Bronner and
Hood, 1983). This suggests that melanocytes also represent an un-
intended target for chemotherapeutic drugs. Several experimental
observations support this concept and suggest that follicular mel-
anocytes are indeed severely a¡ected by chemotherapeutic drugs
(reviewed in Tobin et al, 1999). For example, CYP disrupts folli-
cular melanogenesis in C57BL/6 mice, alters formation of mela-
nosomes, and causes abnormal transfer of pigment granules
to ectopic hair bulb locations, leading to extrafollicular melanin
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incontinence (Slominski et al, 1996). Moreover, chemotherapy
induces profound changes in tyrosinase and DOPA-chrome tau-
tomerase activity in murine skin (Slominski et al, 1996). Also,
electron microscopy data suggest that after CYP treatment some
melanocytes change their localization and migrate to the bottom
of the hair bulb, whereas others undergo apoptosis (Tobin et al,
1998).
In mice, the presence of melanocytes in the epidermis strongly
depends on stem cell factor (SCF) production by epidermal kera-
tinocytes. In normal C57BL/6 mice, melanocytes progressively
disappear from the epidermis of dorsal skin shortly after birth
due to downregulation of SCF and are normally present only in
the HF (Yoshida et al, 1996). In contrast, mice overexpressing SCF
under control of the K14 promoter display hyperpigmentation,
constitutive presence of melanocytes in the interfollicular epider-
mis, and ectopic appearance of melanocytes in atypical areas, in-
cluding nose, mouth, ears, and footpads (Kunisada et al, 1998a;
Kunisada et al, 1998b). Our data suggest that SCF/c-kit signaling
is critical for melanocyte proliferation, di¡erentiation, and/or mi-
gration during the hair cycle, and hence is required for cyclic
regeneration of the hair pigmentation unit postnatally (Botchkar-
eva et al, 2001).
The role for SCF/c-kit signaling in the response of HF mela-
nocytes to chemotherapy remains to be elucidated, however. A
variety of other growth factors including hepatocyte growth fac-
tor, neurotrophins, endothelin-3, and p53 are also implicated in
the control of melanogenesis, melanocyte migration, survival,
and apoptosis during development and postnatal life (reviewed
in Gilchrest et al, 1996; Hearing, 1999; Halaban, 2000). It remains
to be elucidated, however, which molecular pathways are speci¢-
cally involved in the response of HF melanocytes to chemother-
apy. Here, we show by double and triple immuno£uorescence
that CYP administration alters the expression of proteins in-
volved in melanogenesis, apoptosis, proliferation, and migration
in follicular melanocytes of C57BL/6 mice. Furthermore, we
show that Fas signaling is involved in HF melanocyte apoptosis
induced by CYP, whereas c-kit signaling regulates proliferation
and the subsequent migration of follicular melanocytes into the
epidermis.
MATERIALS ANDMETHODS
Animal models and tissue collection C57BL/6 female mice (n¼ 40) 8
wk old and 8^10-wk-old Fas knockout mice (n¼10) and wild-type mice
(n¼10) were purchased from Charles River (Boston, MA) and Jackson La-
boratory (Bar-Harbor, ME). Fas knockout mice generated on C57BL/6
background were viable with apparently normal coat (Adachi et al, 1995).
Mice were housed in community cages at the animal facilities of the Bos-
ton University School of Medicine. All mice were fed water and murine
chow ad libitum, and were kept under 12 h light/dark cycles. Active hair
growth (anagen) was induced in the back skin by application of a wax^
rosin mixture with subsequent depilation, as described before (Paus et al,
1994; 1996). On day 9 after hair cycle induction (at anagen VI stage of the
hair cycle), a single intraperitoneal injection of 150 mg per kg CYP (En-
doxan, Bristol Meyers Squibb, Princeton, NJ) or phosphate-bu¡ered saline
(PBS) (vehicle control) was performed as described previously (Paus et al,
1994; 1996). Skin samples of C57BL/6 mice were harvested at days 1, 3, 5, 7,
9, 11, 16, and 21 after CYP administration (corresponding to days 10, 12, 14,
16, 18, 20, 25, and 30 post depilation, respectively). Skin samples of Fas
knockout mice (n¼10) and wild-type mice (n¼10) were harvested 24^72
h after CYP administration (11^12 d post depilation). Harvesting of skin
and cryosectioning were performed using a special technique to obtain
longitudinal sections of the HFs, as described previously (Paus et al, 1999).
Immunohistochemistry, TUNEL, and multicolor confocal micro-
scopy For immunohistochemical analyses, acetone-¢xed cryostat sec-
tions (8 mm) of adolescent C57BL/6 mouse back skin were used. To study
the expression of melanogenic markers [tyrosinase, tyrosinase-related pro-
teins 1 and 2 (TRP1,TRP2)], we performed an immuno£uorescence pro-
tocol using the corresponding primary rabbit antisera (see Table I) and
secondary tetramethylrhodamine-isothiocyanate (TRITC) conjugated goat
Table I. Primary antibodies
Antibody against Abbreviation
Characterization of
antigen Dilution Species Manufacturer
c-kit receptor c-kit Murine c-kit (Nishikawa et al, 1991;
Botchkareva et al, 2001)
1:1000 Rat Pharmingen, San Diego, CA
Nuclear matrix-
associated proliferation-
related antigen
Ki-67 (TEC-3) Murine Ki-67 (Gerdes et al, 1990;
Botchkarev et al, 1999a)
1:20 Rat Dianova, Hamburg, Germany
Fas/CD95 receptor Fas Murine Fas receptor (Botchkarev et
al, 2000a)
1:1000 Rat Pharmingen, San Diego, CA
p53 protein p53 Murine p53 (Song and Lambert,
1999; Botchkarev et al, 2000a)
1:1000 Rabbit Novocastra, Newcastle, U.K.
p55TNFR p55TNFR Murine tumor necrosis factor type I
receptor (Botchkarev et al, 2000a)
1:500 Rat Pharmingen, San Diego, CA
p75NTR p75NTR Murine p75NTR (Botchkarev et al,
1999a; 1999b; 2000b)
1:500 Rat Chemicon,Temecula, NJ
SCF SCF Murine SCF, clone 40215.11
(Botchkarev et al, 2001)
1:1000 Rat R&D Systems, Minneapolis, MN
Tyrosinase aPEP 7 Polyclonal antiserum against a
synthetic peptide that corresponds to
the carboxyl terminus of Tyr, the
murine albino locus encoded protein
(Jimenez et al, 1991)
1:1000 Rabbit Gift of Dr.V.J. Hearing
Tyrosinase-related-protein-1 TRP1 (aPEP1) Polyclonal antiserum against a
synthetic peptide that corresponds to
the carboxyl terminus of the murine
brown locus encoded protein
(Jimenez et al, 1988)
1:1000 Rabbit Gift of Dr.V.J. Hearing
Tyrosinase-related-protein-2 TRP2 (aPEP8) Polyclonal antiserum against a
synthetic peptide that corresponds to
the carboxyl terminus of the murine
slaty locus encoded protein
(Tsukamoto et al, 1992)
1:1000 Rabbit Gift of Dr.V.J. Hearing
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antirabbit IgG (Jackson ImmunoResearch, West Grove, PA), as described
previously (Botchkareva et al, 2001). Brie£y, cryosections were incubated
with primary antisera overnight at room temperature, followed by applica-
tion of secondary antibody (diluted 1:200) for 45 min at 371C. Incubation
steps were interspersed by four washes with Tris-bu¡ered saline (TBS, 5
min each).
For double immuno-visualization of TRP2 and the proliferative marker
Ki-67, cryosections were ¢rst incubated with rat monoclonal antibody
against murine Ki-67 (see Table I) overnight at room temperature, fol-
lowed by incubation withTRITC-labeled goat antirat IgG (Jackson Immu-
noResearch; 45 min, 371C). After subsequent washing in TBS, sections
were incubated with primary rabbit antiserum against TRP2 overnight at
room temperature followed by incubation with £uorescein isothiocyanate
(FITC) conjugated secondary goat antirabbit rat IgG (Jackson ImmunoRe-
search; 45 min, 371C). Finally, sections were washed three times with TBS
and then counterstained byTO-PRO3-iodide (Molecular Probes, Eugene,
OR) for visualization of cell nuclei (Botchkareva et al, 2001).
For the double immunodetection of c-kit and TRP2, the tyramide am-
pli¢cation method was used, as described before (Botchkareva et al, 2001).
Brie£y, after blocking of endogenous peroxidase and nonspeci¢c avidin/
biotin binding, sections were incubated in TNB bu¡er (DuPont NEN,
Boston, MA) followed by application of a rat monoclonal antibody against
murine c-kit (1:1000) overnight. Then the corresponding biotinylated goat
anti-rat antiserum (1:200, 30 min), diluted in TNB blocking bu¡er (Du-
Pont NEN), was applied. The reaction product was developed using a
commercial tyramide ampli¢cation kit (DuPont NEN). Sections were in-
cubated in streptavidin-horseradish peroxidase (HRP; 1:100 in TNB,
30 min), washed with TNT bu¡er (DuPont NEN), followed by a 10 min
application of TRITC-tyramide (1:50 in Ampli¢cation Diluent, Du Pont
NEN). Then, after blocking nonspeci¢c binding by 10% normal goat
serum, sections were incubated with rabbit antiserum against TRP2,
washed inTBS (35 min), followed by incubation with FITC-conjugated
secondary goat anti-rabbit IgG (45 min, 371C). Finally, sections were
washed three times with Tris bu¡er and then counterstained with TO-
PRO3-iodide for visualization of cell nuclei.
For triple immuno-visualization of c-kit,TRP2, and Ki-67, a method of
simultaneous detection of tissue antigens using antibodies raised from
the same species was applied (Shindler and Roth, 1996). Brie£y, skin cryo-
sections were ¢rst immunostained with rat monoclonal antibody against c-
kit (diluted 1:1000;Table I) followed by the application of biotinylated goat
anti-rat IgG, streptavidin-HRP, and TRITC-tyramide, as described above.
Then sections were processed for visualization of Ki-67 with the corre-
sponding rat monoclonal antibody (diluted 1:50; Table I) overnight at
room temperature followed by the application of Cy-5-conjugated second-
ary goat anti-rat IgG (Jackson ImmunoResearch, 1:50, 45 min at 371C).
According to the original protocols (Shindler and Roth, 1996), rat anti-c-
kit antibody used in the dilution 1:1000 could only be detected by the tyr-
amide ampli¢cation assay. Therefore, anti-c-kit antibody was undetectable
for the Cy5-conjugated goat anti-rat secondary antibody used consecu-
tively for visualizing rat anti-Ki-67 antibody (diluted 1:50). After visualiza-
tion of Ki-67 antigen, rabbit antiserum against TRP2 was applied followed
by incubation with FITC-labeled goat anti-rabbit IgG, as described above.
Thus, this method allowed us to visualize in skin sections simultaneously c-
kit receptor on cell membranes (TRITC-coupled red £uorescence), Ki-67
in the cell nucleus (Cy5-coupled blue £uorescence), and one of the mela-
nogenic proteins in cytoplasm (FITC-coupled green £uorescence).
For the double immuno-visualization of one of the melanogenic pro-
teins and TUNEL, cryostat sections were processed for the detection of
TUNEL-positive apoptotic cells using commercially available Apo-Tag
kit (Intergen, Purchase, NY). Reaction product was visualized by FITC-
labeled anti-digoxigenin antibody. Then, one of the melanogenic proteins
was visualized using the corresponding primary antisera and TRITC-con-
jugated goat anti-rabbit IgG, as described above (Botchkareva et al, 2001),
and nuclei were counterstained with TO-PRO3.
For the analysis of SCF expression, the rat monoclonal antibody against
murine SCF was used (see Table I), and the tyramide ampli¢cation assay
was applied, as described above. Then, sections were counterstained with
TO-PRO3 for visualization of cell nuclei. Negative controls of immunos-
taining were performed by omitting primary antibodies. Skin cryosections
of the SCF overexpressing transgenic mice, which showed ectopic expres-
sion of SCF in the basal epidermal keratinocytes and abundantly contained
melanocytes in the epidermis and mast cells in the dermis (Kunisada et al,
1998a), were used as positive controls for antibodies against SCF, melano-
genic proteins, and c-kit, respectively. HFs in late anagen phase displaying a
high number of proliferating cells in the proximal hair matrix were used as
an internal positive control for the antibody against Ki-67. All slides were
analyzed using a Zeiss confocal microscope, and were photo-documented
using a digital image analysis system (Pixera, San Diego, CA).
Western blot analysis Total tissue proteins were obtained from extracts
of full-thickness C57BL/6 back skin treated either with CYP or with vehi-
cle control. Skin samples were collected in a bu¡er consisting of
0.25 M Tris^HCl (pH7.5), 0.375 M NaCl, 2.5% sodium deoxycholate, 1%
Triton X-100, 25 mM MgCl2, 1 mM phenylmethylsulfonyl £uoride, and
0.1 mg per ml aprotinin, as described before (Botchkareva et al, 2001).
Protein concentrations were determined by the Bradford method and
100 mg of proteins was processed for Western blot analysis as described
previously (Botchkareva et al, 2001). Antibody reaction was performed
with rat monoclonal anti-SCF antibody (1:200; R&D Systems, Minneapo-
lis, MN) or with goat polyclonal anti-b-actin antiserum (1:200, Santa
Cruz Biotechnology, Santa Cruz, CA). HRP-tagged donkey antirat or
goat antirabbit IgG were used as secondary antibodies (Santa Cruz
Biotechnology; Botchkarev et al, 2001). Murine 45 kDa recombinant SCF
protein (R&D Systems) was used as a positive control for anti-SCF anti-
body, and preabsorption of anti-SCF antibody with recombinant SCF
protein was used as negative control. The ECL detection kit (Amersham)
followed by autoradiography (Kodak X-Omatic AR) detected antibody
binding.
Pharmacologic manipulations in vivo Rat monoclonal antibody
ACK45 against mouse c-kit (Pharmingen, San Diego, CA) was adminis-
tered intracutaneously to back skin of the 8-wk-old C57BL/6 mice at a
dose of 6 mg per kg at di¡erent time points after CYP administration.
The speci¢city and activity of this antibody are very similar to those of
the antibody ACK2, and it was reported to block c-kit signaling in vitro
and in vivo (Nishikawa et al, 1991; Yoshida et al, 1996; Botchkareva et al,
2001). Intradermal administration of the same concentrations of mouse
normal serum was used as a vehicle control. ACK45 treatment was per-
formed on days 2, 4, and 6 after CYP administration (days 11, 13, and 15
post depilation, respectively). Skin samples from ¢ve control and ¢ve
ACK45-treated mice were analyzed 1 d after the last administration of
ACK45 (on day 7 after CYP administration, corresponding to day 16 post
depilation).
Morphometry and statistical analysis In the back skin, more than 50
HFs at each time point after CYP administration, derived from three to
¢ve di¡erent mice, were studied for each antigen analyzed. Only every
tenth cryosection was used for analysis in order to exclude the repetitive
evaluation of the same HF, and two to three cryosections were assessed
from each animal. For the analysis of melanocyte apoptosis, cryosections
of the Fas null and wild-type skin harvested 24^72 h after CYP adminis-
tration were used. At least 60^70 HFs at catagen II and catagen III stages
were analyzed, and the percentage of TUNEL/TRP2 double positive mel-
anocytes per total number of TRP2-positive melanocytes in the hair bulb
was assessed. All sections were analyzed at 200^400magni¢cation, and
means and SEM were calculated from pooled data. Di¡erences were
judged as signi¢cant if the p-value was lower than 0.05, as determined by
the independent Student’s t test for unpaired samples.
RESULTS
CYP administration alters the expression of melanogenic
proteins and causes apoptosis, proliferation, and migration
in HF melanocytes Hair growth phase (anagen) was induced
by depilation in C57BL/6 mice, as described before (Paus et al,
1994). CYP was administered 9 d post depilation, i.e., at the
time point when all HFs actively produce a hair shaft (anagen
VI). To study the expression of melanogenic proteins in di¡erent
subpopulations of follicular melanocytes after CYP
administration, tissue sections of C57BL/6 mouse skin were
stained with antisera against melanogenic proteins (TRP2,
TRP1, and tyrosinase), as described previously (Botchkareva et
al, 2001). We performed double immunostainings for these
melanogenic proteins and TUNEL at distinct stages of CYP-
induced HF regression to determine apoptosis in these cells.
To visualize whether di¡erent subpopulations of the HF
melanocytes proliferate after CYP administration, double
immuno£uorescence for one of the melanogenic proteins and
the proliferative marker Ki-67 was employed.
Twenty-four hours after the beginning of the experiment (10 d
post depilation), HFs treated by vehicle control prominently
expressed tyrosinase in melanogenically active melanocytes that
located above the dermal papilla (Fig 1A). These melano-
cytes also expressed TRP1 and TRP2 (data not shown). Single
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TRP1-positive melanocytes were also seen in the outer root
sheath (Fig 1B), and single TRP2-positive cells were rarely
present in the outer root sheath and bulge (not shown). This
expression pattern was fully consistent with that described
previously for murine anagen HFs (Botchkareva et al, 2001) and
was associated with absence of TUNEL-positive cells in the hair
bulb (Fig 1A).
Consistent with data described before (Lindner et al, 1997;
Botchkarev et al, 2000a), 24 h after the beginning of the
experiment (10 d post depilation) CYP-treated HFs displayed
numerous TUNEL-positive apoptotic cells located in the HF
matrix (Fig 1C). In CYP-treated HFs, melanocytes expressing
all three melanogenic proteins were seen not only above the
dermal papilla, but also at the bottom part of the proximal hair
Figure1. Expression of melanogenic proteins,TUNEL, and Ki-67 in the HF melanocytes after CYP treatment.The hair cycle was induced in
the back skin of 8-wk-old C57BL/6 mice by depilation, and CYP was administered after 9 d. Skin was harvested at the indicated time points after CYP
administration, and cryosections (8 mm thickness) were processed for the double immuno-visualization of TRP1, TRP2, tyrosinase, TUNEL, and Ki-67
(A^N, P), or stained by hematoxylin (O, Q). In (A)^(N), nuclei are counterstained byTO-PRO3M. (A), (B) Nontreated control anagen HFs. (A) Prominent
expression of tyrosinase (arrow) and lack of TUNEL-positive cells in the hair bulb. (B) Single TRP1-positive melanocytes (arrows) and single TUNEL-
positive cells (arrowhead) are seen in the outer root sheath. (C)^(F) HFs 24 h after CYP treatment. (C) NumerousTUNEL-positive cells (green £uorescence)
in the hair matrix (arrows). (D) Appearance of TRP1 expression (red £uorescence) at the base of the hair bulb (arrow). TUNEL-positive keratinocytes (green
£uorescence) are shown by arrowheads. (E) Colocalization of TRP2 and TUNEL (yellow £uorescence) in single melanocytes at the bottom of the hair
matrix (arrow). (F) Single tyrosinase-positive hair bulb melanocytes showTUNEL-positive granules (yellow £uorescence, arrowheads). (G)^(I) HFs 48 h after
CYP treatment. (G) Colocalization of TRP1 and TUNEL in the hair bulb (yellow £uorescence, arrowheads). (H) Colocalization of tyrosinase and TUNEL
in the hair bulb (arrows). (I) Lack of TUNEL inTRP2-positive melanocytes of the outer root sheath (arrows). (J), (K) HFs 72 h after CYP treatment. (J) Lack
of TUNEL in TRP1-positive melanocytes located in the regressing hair bulb and outer root sheath (red £uorescence, arrows). (K) Ki-67-positive nucleus
(red £uorescence) in TRP2-positive melanocyte (green £uorescence) at the base of the hair bulb (arrow). Lack of Ki-67 immunoreactivity in nuclei of two
other melanocytes (arrowheads). (L)(O) Skin 5^7 d after CYP treatment. (L) NumerousTRP1-positive melanocytes (red £uorescence) are visible alongside
the outer root sheath (arrows) and in the epidermis (arrowheads). (M) TRP2-positive melanocytes (red £uorescence) in the HF (arrows) and in interfollicular
epidermis (arrowheads). (N) Tyrosinase-positive melanocytes are only visible in the interfollicular epidermis (arrowheads) and in the supra-infundibular outer
root sheath of the HF (arrow). (O) Numerous melanin granules are visible in epidermis of CYP-treated skin (arrows). Suprabasal epidermal keratinocyte with
melanin granules around the nucleus is shown by arrowhead. (P), (Q) Control skin at day 16 post depilation. (P) TRP2-positive melanocytes are only visible
in the outer root sheath (arrows) and are absent in the epidermis. (Q) Lack of melanin in the epidermis of control skin. DP, dermal papilla; EP, epidermis;
IRS, inner root sheath; ORS, outer root sheath. Scale bars: (A)^(G), (K), (O), (Q) 50 mm; (H)^(J), (L)^(N), (P) 100 mm.
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matrix (Fig 1D^F). Only single TUNEL-positive melanocytes
were seen in the hair bulb, however (Fig 1E, F). No TUNEL-
positive melanocytes were found in the outer root sheath or
bulge (not shown) 24 h after CYP administration. Also, 24 h
after CYP treatment no expression of the proliferative marker
Ki-67 was seen in any subpopulation of follicular melanocytes
(data not shown).
Forty-eight hours after CYP administration (11 d after
depilation), the number of TUNEL-positive melanocytes in the
proximal hair matrix was increased (Fig 1G,H). NoTUNELwas
found in melanocytes located in the outer root sheath, however
(Fig 1I), or bulge (not shown). Also, no expression of the
proliferative marker Ki-67 was seen in follicular melanocytes
48 h after CYP treatment (data not shown).
Consistent with previous reports (Paus et al, 1994; 1996; Lindner
et al, 1997; Botchkarev et al, 2000a), 72 h after CYP administration
(day 12 post depilation), HFs shortened their length due to the
massive apoptosis in the proximal hair bulb. At this time point,
the number of melanocytes expressingTRP1 (Fig 1J),TRP2, and
tyrosinase (not shown) in the regressing hair bulb was also
reduced, compared to the vehicle control. No colocalization of
melanogenic markers and TUNEL was seen in the hair bulb
(Fig 1J), outer root sheath, or bulge (not shown). Instead, some
TRP2-positive melanocytes located in the regressing hair bulb
coexpressed the proliferative marker Ki-67, suggesting their
entry into the cell cycle (Fig 1K). No coexpression of Ki-67 was
seen in TRP2-positive melanocytes located in the outer root
sheath or bulge, however (not shown).
HF length was substantially reduced 5^7 d after CYP
administration (14^16 d post depilation), as previously reported
for HFs entering terminal stages of CYP-induced regression
accompanied by hair loss (Paus et al, 1994). In the outer root
sheath, however, these HFs showed a large number of
melanocytes that expressed TRP1 and TRP2 and were
tyrosinase- and Ki-67-negative (Fig 1L, M). Most interesting,
numerous melanocytes expressing all three melanogenic proteins
(TRP1, TRP2, tyrosinase) were seen in the interfollicular
epidermis of CYP-treated skin (Fig 1L^N). These melanocytes
showed numerous melanin granules, consistent with their
melanogenic activity (Fig 1O). In contrast, no melanocytes
expressing any of these melanogenic proteins (Fig 1P) or
melanin granules (Fig 1Q) were seen in the interfollicular
epidermis of control skin. Melanocytes located in the epidermis
of CYP-treated skin did not show expression of Ki-67 or
TUNEL and persisted up to 3 wk after the beginning of the
experiment (not shown).
Thus, distinct subpopulations of HF melanocytes showed
di¡erential response to CYP treatment. Whereas selected hair
bulb melanocytes underwent apoptosis 24^48 h after CYP
administration, no cell death was seen in the outer root sheath
and bulge melanocytes. Seventy-two hours after CYP
administration, the surviving hair bulb melanocytes were
proliferative and later migrated up the outer root sheath to the
interfollicular epidermis. Five to seven days after CYP treatment,
numerous melanocytes expressing all three melanogenic proteins
had repopulated the epidermis and showed melanogenic activity.
After CYP treatment, apoptotic melanocytes in the HFs
express Fas, whereas proliferating and migrating follicular
melanocytes express c-kit To explore the mechanisms
underlying apoptosis, proliferation, and migration in distinct
subpopulations of HF melanocytes after CYP administration,
we performed double immunostaining for the melanogenic
protein TRP2 and a variety of markers implicated in
melanocyte apoptosis [Fas, p55TNFR, p75 kDa neurotrophin
receptor (p75NTR), and p53] and/or proliferation and migration
(c-kit) (reviewed in Pincelli and Yaar, 1997; Tobin et al, 1999;
Halaban, 2000). TRP2 was selected as the melanocyte marker
because it depicts the largest number of melanocytes in intact
anagen HFs (Botchkareva et al, 2001) as well as in CYP-treated
murine HFs (Fig 1).
Because TUNEL-positive melanocytes were mostly seen in
proximal hair bulb 48 h after CYP administration (Fig 1G, H),
colocalization of TRP2 and apoptotic markers was studied in
HFs 24^48 h after the beginning of the experiment. Twenty-
four hours after CYP administration, Fas expression was seen in
the hair matrix (Fig 2A). Colocalization of Fas and TRP2 was
found in a portion of hair bulb melanocytes (Fig 2A). No
expression of the two other ‘‘death’’ family receptors, however,
namely p55TNFR (Fig 2B) and p75NTR (Fig 2C), was seen in
hair bulb melanocytes. Also, no p53 expression was found in hair
bulb melanocytes, whereas prominent p53 immunoreactivity was
seen in hair matrix and outer root sheath keratinocytes (Fig 2D).
This suggested that, among the apoptotic markers tested, Fas
signaling may principally be involved in mediating apoptosis in
hair bulb melanocytes after CYP treatment, at least at the time
points examined.
To explore mechanisms that control proliferation of HF
melanocytes and their migration into the epidermis after CYP
administration, we focused on the possible involvement of c-kit.
As shown previously, SCF and its receptor c-kit are critically
important for the migration, proliferation, and di¡erentiation of
melanoblasts during embryogenesis (reviewed in Galli et al,
1994; Lecoin et al, 1999). Furthermore, c-kit blockade during
the postnatal hair cycle alters melanocyte proliferation
and migration and leads to formation of unpigmented hairs
(Botchkareva et al, 2001). To examine whether HF melano-
cytes express c-kit receptor after CYP treatment, double
immuno£uorescence for TRP2 and c-kit was performed, as
described before (Botchkareva et al, 2001).
Interestingly, no expression of c-kit was seen on TUNEL-
positive melanocytes in the proximal hair bulb 48 h after CYP
administration (Fig 2E). Conversely, c-kit-positive melanocytes
in the hair bulb were TUNEL-negative (Fig 2E). Seventy-two
hours after CYP administration, selected TRP2-positive
melanocytes in the proximal hair bulb expressed both c-kit and
proliferative marker Ki-67, suggesting their entry into the cell
cycle (Fig 2F). Simultaneous immunodetection of TRP2, c-kit,
and Ki-67 showed that c-kit was expressed on both proliferating
and nonproliferating TRP2-positive melanocytes (Fig 2F).
Ninety-six hours after CYP treatment, many TRP2-positive
melanocytes in the outer root sheath also showed c-kit
expression (Fig 2G), and 5^7 d after CYP treatment TRP2-
positive melanocytes located in the HF outer root sheath and in
the interfollicular epidermis also showed c-kit expression (Fig
2H). In addition, c-kit expression was seen on tyrosinase-
positive melanogenically active melanocytes in the epidermis 7 d
after CYP administration (Fig 2I). These data suggested that
SCF/c-kit signaling may contribute to proliferation and
migration of c-kit-positive follicular melanocytes into the
epidermis after CYP treatment.
Fas signaling is involved in the control of apoptosis in HF
melanocytes after CYP administration To test the role of
Fas in HF melanocyte apoptosis after CYP administration, the
percentage of TUNEL-positive and TUNEL-negative hair bulb
melanocytes was calculated and compared between HFs of wild-
type mice and Fas knockout (/) mice 48^72 h after CYP
administration. At 48 h, Fas knockout mice showed a signi¢cant
reduction (po0.01) in the number of apoptotic or TRP2/
TUNEL double positive melanocytes in the hair bulb,
compared to wild-type mice (Fig 2J^L). At 72 h, when all
TUNEL-positive melanocytes disappeared from the HFs of
wild-type skin, double TRP2/TUNEL-positive melanocytes
were still seen in HFs of Fas knockout mice (data not shown).
Thus, CYP-induced apoptosis in hair bulb melanocytes with
constitutive deletion of Fas developed more slowly, supporting
our hypothesis that Fas participates in apoptotic elimination of
selected follicular melanocytes after CYP treatment.
SCF protein is upregulated in skin and in the interfollicular
epidermis after CYP treatment SCF/c-kit signaling is
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involved in regulation of melanocyte proliferation, dif-
ferentiation, and melanogenic activity during the postnatal
hair cycle in mice (Botchkareva et al, 2001). To study the
expression of SCF in skin after CYP administration, both
Western blot analysis and immunohistochemistry were
employed. By Western blotting, SCF protein decreased in skin
24 h after CYP administration, compared to control skin (Fig
3A). Ninety-six hours after CYP administration, however, an
increase of SCF protein was seen in full-thickness lysates from
CYP-treated skin, compared to control skin (Fig 3A).
Furthermore, a marked upregulation of SCF protein was seen
on day 7 after CYP administration, compared to control skin
(Fig 3A).
By immunohistochemistry, SCF expression was seen in the HF
dermal papilla and connective tissue sheath, in HF cells located
above the dermal papilla, as well as in dermal ¢broblasts of
control anagen skin (Fig 3B). Seventy-two hours after CYP
treatment, SCF expression in the dermal papilla was increased
(Fig 3C). Compared to control skin, 5^7 d after CYP
administration SCF expression was markedly increased in the
interfollicular epidermis and in the HF connective tissue sheath
(Fig 3D, E). These two sets of data suggest that marked
upregulation of SCF protein in the interfollicular epidermis of
CYP-treated skin supports proliferation and migration of the c-
kit-positive melanocyte subpopulation from the HFs.
Administration of c-kit neutralizing antibody prevents
CYP-induced migration of melanocytes from the HF into
the epidermis To explore whether SCF/c-kit signaling is
involved in the control of proliferation and migration of the c-
kit-positive melanocyte subpopulation into the epidermis after
CYP treatment, anti-c-kit monoclonal antibody (ACK45) was
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intradermally administered into the C57BL/6 mouse skin 2, 4,
and 6 d after CYP treatment (11, 13, and 15 d after depilation;
Fig 4A). As shown previously, this commercially available
analog of the ACK2 antibody blocked c-kit signaling in vitro and
in vivo (Nishikawa et al, 1991;Yoshida et al, 1996; Botchkareva et al,
2001). Skin samples treated by vehicle control or by ACK45
antibody were analyzed 1 d after the ¢rst or last administration
of ACK45 (3 or 7 d after CYP administration, or on days 12 and
16 post depilation, respectively; Fig 4A).
One day after ¢rst ACK45 administration (on day 12 post
depilation), no TRP2/TUNEL double positive melanocytes
were seen in ACK45-treated and control HFs (data not shown).
This suggested that ACK45 treatment does not a¡ect apoptosis in
HF melanocytes induced by CYP. The number of TRP2/Ki-67
double positive (proliferating) melanocytes was signi¢cantly
reduced in HFs after ACK45 treatment, however (0.570.12 per
HF), compared to vehicle control (2.270.37 per HF, pp0.05).
These data correspond well with our previous results
(Botchkareva et al, 2001), suggesting that ACK45 treatment,
although inhibiting proliferation and migration of HF
melanocytes, does not induce apoptosis in these cells.
On day 16 post depilation (or 1 d after the last ACK45
treatment), the number of TRP2-positive melanocytes in
the intrafollicular epidermis (1.370.2 per microscopic ¢eld,
Fig 4B) was signi¢cantly reduced (po0.001), compared to
vehicle control (11.572.3 per microscopic ¢eld, Fig 4C). Also,
the number of TRP2-positive melanocytes in the outer root
sheath was markedly decreased after ACK45 treatment,
compared to vehicle control (Fig 4B, C). Interestingly,
tyrosinase-positive melanocytes seen in the epidermis 7 d
after CYP administration completely disappeared from the
epidermis of ACK45-treated skin (not shown). This suggests
that SCF/c-kit signaling is indeed involved in the control of
CYP-induced proliferation and migration of the c-kit-positive
melanocyte subpopulation from the HF into the interfollicular
epidermis.
DISCUSSION
The HF response to chemotherapy is a pathobiologic process
leading to organ involution after DNA damage in rapidly prolif-
erating cells of the follicular epithelium. Consistent with data
published previously (Slominski et al, 1996; Tobin et al, 1998;
1999), we now show that HF melanocytes are also profoundly af-
fected by chemotherapy. Speci¢cally, using the C57BL/6 mouse
model for chemotherapy-induced hair loss (Paus et al, 1994; Lind-
ner et al, 1997), we demonstrate that the response of the follicular
melanocytes to chemotherapy is more complex than previously
appreciated.Whereas some hair bulb melanocytes undergo apop-
tosis after CYP administration, others proliferate, migrate up the
HF outer root sheath, and later repopulate interfollicular epider-
mis (Fig 1).
In anagen HF, melanocytes located above the upper part of
dermal papilla actively produce and transport melanin into di¡er-
entiating hair shaft keratinocytes (Slominski et al, 1991; 1994; Slo-
minski and Paus, 1993; reviewed in Tobin et al, 1999). During
catagen, melanogenic activity in hair bulb melanocytes ceases
and some of them are present in regressing epithelial strand
(Commo and Bernard, 2000). After chemotherapy, many hair
matrix keratinocytes rapidly undergo apoptosis (Lindner et al,
1997; Soma et al, 1998). Simultaneously, there are severe alterations
in the activity of hair bulb melanocytes with some newly visible
among the apoptotic keratinocytes at the bottom of the regres-
sing hair bulb (Fig 1D^F). This is fully consistent with electron
microscope data published previously that show relocation of
melanogenic melanocytes to ectopic regions of the hair bulb 1 d
after CYP administration (Slominski et al, 1996; Tobin et al, 1999).
We show that 48 h after CYP administration selected hair bulb
melanocytes are TUNEL-positive indicating on-going apoptosis
(Fig 1G, H). Again, these observations are consistent with elec-
tron microscope data published previously (Tobin et al, 1999). In-
terestingly, our double immuno-visualization studies suggest that
p53 protein, which is essential for CYP-induced apoptosis in HF
keratinocytes (Botchkarev et al, 2000a), is not detectable by our
immunostaining protocol in hair bulb melanocytes after CYP
administration (Fig 2D). Also, among the other apoptotic mar-
kers studied (p55TNFR, p75NTR, p53), only Fas was detected
in hair bulb melanocytes after CYP treatment (Fig 2A). Further-
more, the number of TUNEL-positive melanocytes in the HFs
of Fas knockout (^/^) mice 48 h after CYP administration is sig-
ni¢cantly lower than in wild-type mice (Fig 2J, K). These data
suggest that Fas is involved in apoptotic elimination of hair bulb
-
Figure 2. Expression of apoptotic markers and c-kit receptor in the HF melanocytes and signi¢cant reduction of apoptotic melanocytes in
the HFs of Fas knockout mice after CYP treatment. The hair cycle was induced in the back skin of 8-wk-old C57BL/6 wild-type mice or in Fas
knockout mice by depilation, and CYP was administered after 9 d. Skin was harvested 1^7 d after CYP administration. Cryosections (8 mm thickness) were
processed for the double immuno-visualization of TRP2 and one of the apoptotic markers (A^D),TRP2 and c-kit receptor (G, H),TRP2 and tyrosinase
(I), or for triple immuno-visualization of TRP2, c-kit, and TUNEL (E) and TRP2, c-kit, and Ki-67 (F). In Fas knockout and wild-type mice, cryosections
were processed for the double immuno-visualization of TRP2 andTUNEL, and the percentage of TUNEL/TRP2 double positive (apoptotic)melanocytes
per total number of TRP2-positive hair bulb melanocytes was compared between wild-type and Fas null HFs (J^K). In (A)^(D), (G)^(I), (K), (L) nuclei are
counterstained byTO-PRO3. (A)^(D) Covisualization of apoptotic markers (red £uorescence) and TRP2 (green £uorescence) in the HF 24 h after CYP
treatment. (A) Colocalization of Fas and TRP2 (yellow £uorescence) in selected hair bulb melanocytes (arrows). (B) Lack of p55TNFR expression in hair
bulb melanocytes (arrows) and strong p55TNFR immunoreactivity in the outer and inner root sheath (small and large arrowheads, respectively). (C) Lack of
p75NTR expression in hair bulb melanocytes (arrows) and strong p75NTR immunoreactivity in the outer root sheath (arrowheads). (D) Prominent p53
expression in the hair bulb keratinocytes and lack of p53 immunoreactivity in melanocytes (arrows). (E)^(I) Covisualization of c-kit, one of the melanogenic
proteins, and TUNEL or Ki-67 in the HFs 2^7 d after CYP treatment. (E) TUNEL (green £uorescence) + c-kit (red £uorescence) + TRP2 (blue £uores-
cence). All c-kit/TRP2 double positive melanocytes (red membrane and blue cytoplasm) are TUNEL-negative (arrowheads). Single TRP2-positive/c-kit-
negative melanocytes (blue £uorescence) showTUNEL-positive granules (green £uorescence, arrow). (F) TRP2 (green £uorescence) + c-kit (red £uorescen-
ce)+Ki-67 (blue £uorescence). Ki-67-positive nucleus is seen in one of the c-kit/TRP2 double positive cells (large arrow) and in oneTRP2 single positive cell
(small arrow) in HF 72 h after CYP treatment. No Ki-67 immunoreactivity is seen in one c-kit/TRP2 double positive cell (large arrowhead) and in oneTRP2
single positive cell (small arrowhead). (G) TRP2 (green £uorescence) + c-kit (red £uorescence). C-kit/TRP2 double positive cells are seen in the outer root
sheath 96 h after CYP treatment (yellow £uorescence, arrows). (H) TRP2 (green £uorescence) + c-kit (red £uorescence). C-kit/TRP2 double positive cells
are seen in the interfollicular epidermis 5 d after CYP treatment (yellow £uorescence, arrows). (I) Tyrosinase (green £uorescence) + c-kit (red £uorescence).
Numerous c-kit/tyrosinase double positive cells are seen in the interfollicular epidermis 7 d after CYP treatment (yellow £uorescence, arrows). (J) Percentage
of TUNEL/TRP2 double positive cells per total number of TRP2-positive hair bulb melanocytes is signi¢cantly reduced in Fas null HFs compared to
wild-type follicles (npp0.01, Student’s t test). (K), (L) TRP2 (green £uorescence)+Fas (red £uorescence). Numerous TUNEL/TRP2 double positive mela-
nocytes (yellow £uorescence) are seen in wild-type HF (K, arrows). Only one out of six TRP2-positive melanocytes shows TUNEL-positivity in Fas null
HF (L, arrow, yellow £uorescence), whereas the others are TUNEL-negative (L, small arrowheads, red £uorescence). TUNEL-positive and TRP2-negative
apoptotic keratinocytes in (K), (L) (green £uorescence) are indicated by large arrowheads. DP, dermal papilla; EP, epidermis; IRS, inner root sheath; ORS,
outer root sheath. Scale bars: 50 mm.
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melanocytes, whereas other apoptotic receptors (p55TNFR,
p75NTR) or p53 most probably play no role in melanocyte
apoptosis after CYP treatment.
We also show that, despite a rapid process of HF involution, 72
h after CYP treatment selected hair bulb melanocytes express Ki-
67 antigen suggesting that they are proliferating (Fig 1K). Four to
¢ve days after CYP administration, the number of intrafollicular
melanocytes increases and they become abundant in the HF outer
root sheath, followed a few days later by their appearance in the
interfollicular epidermis (Fig 1L^O). These data are consistent
with observations suggesting increased DOPA-chrome tautomer-
ase activity in C57BL/6 skin 5^7 d after CYP administration
(Slominski et al, 1996). Interestingly, melanocytes located in the
outer root sheath of regressing HFs express only TRP1 and
TRP2 (Fig 1L, M), whereas epidermal melanocytes in addition
to TRP1 and TRP2 express tyrosinase and show numerous mel-
anin granules, consistent with melanogenic activity (Fig 1N, O).
In normal epidermis of murine back skin, melanocytes are
visible only during late embryogenesis and they progressively
disappear from the epidermis shortly after birth, presumably due
to downregulation of SCF production by epidermal keratino-
cytes (Yoshida et al, 1996). In normal postnatal mice, melanocytes
are only present in the HFs, although SCF overexpression in basal
epidermal keratinocytes (promoter K14) is accompanied by the
appearance of melanocytes in the epidermis (Kunisada et al,
1998a; 1998b). We show by Western blotting and immunocyto-
chemistry that, in CYP-treated C57BL/6 murine skin, SCF pro-
tein is markedly upregulated and increased in the interfollicular
epidermis compared to control skin (Fig 3).
Furthermore, we show that proliferating and migrating HF
melanocytes express the SCF receptor c-kit and that melanogeni-
cally active epidermal melanocytes in CYP-treated skin are also
c-kit-positive (Fig 2F^I). As CYP-induced melanocyte migra-
tion from the HF into the interfollicular epidermis is completely
abrogated by administration of c-kit neutralizing antibody
ACK45 (Fig 4), we conclude that SCF/c-kit signaling plays an
important role in HF melanocyte proliferation and/or migration
from the HF after chemotherapy. It remains to be determined
whether melanocytes repopulating the epidermis are derived
from those cells that may survive CYP treatment or from mela-
nocyte stem cells in the HF bulge (Nishimura et al, 2002).
Several observations published previously suggest that che-
motherapy is often accompanied by skin hyperpigmentation (re-
viewed in Bronner and Hood, 1983; Susser et al, 1999; Koppel and
Boh, 2001). Also, it was observed that subcutaneous SCF admin-
istration induces cutaneous hyperpigmentation associated with
Figure 3. SCF protein is upregulated in skin and interfollicular epi-
dermis after CYP treatment. The hair cycle was induced in the back
skin of 8-wk-old C57BL/6 mice by depilation, and CYP or PBS was admi-
nistered after 9 d. Skin was harvested 1^7 d after CYP or PBS administra-
tion. Western blotting assay of the extracts of the full-thickness skin was
performed to detect SCF protein or b-actin (A). Cryostat sections were
processed for the determination SCF immunoreactivity (B)^(E). (A) Wes-
tern blot analysis of the control and CYP-treated skin. Positive control was
performed with recombinant murine 45 kDa SCF protein. (B) Control
anagen skin (day 12 post depilation). SCF expression on the dermal papilla
(arrow), in cells that are located above the dermal papilla (arrowhead), and in
the dermis. (C) Skin 72 h after CYP treatment (day 12 post depilation).
Increase of SCF expression in the dermal papilla (arrow) and in the dermis.
(D) Control skin at day 16 post depilation. Relatively weak SCF immunor-
eactivity in the epidermis (arrow) and dermis. (E) Skin 7 d after CYP treat-
ment (day 16 post depilation). Marked increase of SCF expression in the
epidermis (arrows), dermis, and HFs (arrowheads). EP, epidermis. Scale bars:
50 mm.
Figure 4. SCF/c-kit signaling is required for the migration of HF
melanocytes into the epidermis after CYP treatment. Hair cycle
was induced by depilation in the back skin of 8-wk-old C57BL/6 mice,
and CYP was administered after 9 d. (A) c-kit neutralizing ACK45 anti-
body or vehicle controls were administered intracutaneously at days 2, 4,
and 6 after CYP administration (on days 11, 13, and 15 after depilation).
Skin was harvested 1 d after the last injection of ACK45 antibody (7 d after
CYP administration). Cryostat sections were immunostained with antiser-
um against TRP2 (B)^(C). (B), (C) Control skin 7 d after CYP administra-
tion shows numerous TRP2-positive melanocytes in the epidermis (B,
arrows) and in the supra-infundibular HF outer root sheath (B, arrowheads).
NoTRP2-positive melanocytes are seen in the epidermis of ACK45-trea-
ted skin (C), although single melanocytes are present in the outer root
sheath below the sebaceous gland (C, arrows). Scale bars: 50 mm.
Figure 5. Fate of melanocytes during HF response to CYP. After
CYP treatment, some of the hair bulb melanocytes undergo apoptosis,
which at least in part is mediated by Fas signaling. The majority of HF
melanocytes proliferate, however, and appear to migrate up the HF outer
root sheath and later repopulate interfollicular epidermis. The latter process
is dependent on SCF/c-kit signaling and may be abrogated by administra-
tion of c-kit neutralizing antibody.
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increased number of melanocytes, melanocyte dendrite exten-
sion, and melanin content (Grichnik et al, 1995). These data, to-
gether with our results, suggest that increase in cutaneous and
epidermal SCF levels may contribute to chemotherapy-induced
skin hyperpigmentation.
Our data on the response of HF melanocytes to CYP treat-
ment are schematized in Fig 5. Based on the di¡erential response
of hair bulb melanocytes to chemotherapy (apoptosis versus pro-
liferation/migration), we suggest that melanogenically active mel-
anocytes in anagen HFs represent a heterogeneous cell
population. We hypothesize that some melanocytes in anagen
HFs are already destined for apoptosis during the anagen^catagen
transition, whereas others are programmed to survive. It is not
yet clear what might determine such heterogeneity, although
ability to express c-kit and/or Fas is contributory. Activation of
the Fas signaling pathway may be a dependent or separate inde-
pendent determinant, and involvement of other gene products is
also likely in the response of follicular melanocytes to che-
motherapy. Factors determining the behavior of the presumptive
‘‘stem cells’’ in HF melanocytes (Nishimura et al, 2002) after che-
motherapy treatment also remain to be elucidated. Elucidation
of such pathways should assist in generating drugs that prevent
or decrease unwanted hyperpigmentation associated with
chemotherapy.
Dr.V. Hearing is gratefully acknowledged for providing antisera againstTRP1,TRP2,
and tyrosinase.This study was supported in part by grants from theAmerican Cancer
Society (IRG-72-001-26-IRG) to V.A.B. and the Carl J. Herzog Foundation to
B.A.G.
REFERENCES
Adachi M, Suematsu S, Kondo T, Ogasawara J, Tanaka T, Joshida N, Nagata S: Tar-
geted mutation in the Fas gene causes hyperplasia in peripheral lymphoid or-
gans and liver. Nat Genet 11:294^300, 1995
Botchkarev VA: Molecular mechanisms of chemotherapy-induced hair loss. J Invest
Dermatol Symp Proc in press 2003
BotchkarevVA, Botchkareva NV, RothW, et al: Noggin is a mesenchymally-derived
stimulator of hair follicle induction. Nature Cell Biol 1:158^164, 1999a
Botchkarev VA, Botchkareva NV,Welker P, et al: A new role for neurotrophins: in-
volvement of brain-derived neurotrophic factor and neurotrophin-4 in hair
cycle control. FASEB J 13:395^410, 1999b
BotchkarevVA, Komarova EV, Siebenhaar F, et al: p53 is essential for chemotherapy-
induced hair loss. Cancer Res 60:5002^5006, 2000a
Botchkarev VA, Botchkareva NV, Albers KM, Chen L-H,Welker P, Paus R: A role
for p75 neurotrophin receptor in the control of apoptosis-driven hair follicle
regression. FASEB J 14:1931^1942, 2000b
Botchkareva NV, Khlgatian M, Longley BJ, BotchkarevVA, Gilchrest BA: SCF/c-kit
signaling is required for cyclic regeneration of hair pigmentation unit. FASEB J
15:645^658, 2001
Bronner AK, Hood AF: Cutaneous complications of chemotherapeutic agents. J Am
Acad Dermatol 9:645^663, 1983
Cece R, Cazzaniga S, Morelli D, et al: Apoptosis of hair follicle cells during doxor-
ubicin-induced alopecia in rats. Lab Invest 75:601^609, 1996
Commo S, Bernard BA: Melanocyte subpopulation turnover during the human hair
cycle: an immunohistochemical study. Pigment Cell Res 13:253^259, 2000
Cotsarelis G: The hair follicle: dying for attention. AmJ Pathol 151:1505^1509, 1997
Cotsarelis G, Millar SE:Towards a molecular understanding of hair loss and its treat-
ment.Trends Mol Med 7:293^301, 2001
Galli SJ, Zsebo KM, Geissler EN:The kit ligand, stem cell factor. Adv Immunol 55:1^
96, 1994
Gerdes J, Scholzen T, Gerlach C, Kubbutat MHG, Zentgraf H: Assessment of cell
proliferation in murine tissues with a polyclonal antiserum against the murine
Ki-67 protein. Eur J Cell Biol 72 (Suppl. 43):88, 1990
Gilchrest BA, Park HY, Eller MS,Yaar M: Mechanisms of ultraviolet light-induced
pigmentation. Photochem Photobiol 63:1^10, 1996
Grichnik JM, Crawford J, Jimenez F, et al: Human recombinant stem-cell factor in-
duces melanocytic hyperplasia in susceptible patients. J Am Acad Dermatol
33:577^583, 1995
Halaban R:The regulation of normal melanocyte proliferation. Pigment Cell Res 13:4^
14, 2000
Hearing VJ: Biochemical control of melanogenesis and melanosomal organization.
J Invest Dermatol Symp ProcThe 4:24^28, 1999
Hubbard SM: Chemotherapy-induced alopecia. Clin Oncol 4:387^457, 1985
Hussein AM: Chemotherapy-induced alopecia: new developments. Southern
Med J 86:489^496, 1993
Jimenez M, Kameyama K, MaloyW,TomitaY, Hearing VJ: Mammalian tyrosinase.
biosynthesis, processing, and modulation by melanocyte-stimulating hormone.
Proc Natl Acad Sci USA 85:3830^3834, 1988
Jimenez M, Tsukamoto K, Hearing VJ: Tyrosinases from two di¡erent loci are ex-
pressed by normal and by transformed melanocytes. J Biol Chem 266:1147^
1156, 1991
Koppel RA, Boh EE: Cutaneous reactions to chemotherapeutic agents. AmJ Med Sci
321:327^335, 2001
Kunisada T, Lu SZ, Yoshida H, et al: Murine cutaneous mastocytosis and epidermal
melanocytosis induced by keratinocyte expression of transgenic stem cell fac-
tor. J Exp Med 187:1565^1573, 1998a
Kunisada T,Yoshida H,Yamazaki H, et al: Transgene expression of steel factor in the
basal layer of epidermis promotes survival, proliferation, di¡erentiation and
migration of melanocyte precursors. Development 125:2915^2923, 1998b
Lecoin L, Dupin E, Le Douarin N: Development of melanocytes from neural
crest progenitors. In: Chuong C-M, ed. Molecular Basis of Epithelial Appendage
Morphogenesis. Austin,TX: R.G. Landes, 1999: pp 131^154
Lindner G, BotchkarevVA, Botchkareva NV, Ling G, van der Veen C, Paus R: Ana-
lysis of apoptosis during hair follicle regression (catagen). AmJ Pathol 151:1601^
1617, 1997
Lindner G, Menrad A, Gehrardi E, et al: Involvement of hepatocyte growth factor/
scatter factor and Met receptor signaling in hair follicle morphogenesis and
cycling. FASEB J 14:319^332, 1999
Nishimura EK, Jordan SA, Oshima H, et al: Dominant role of the niche in melano-
cyte stem-cell fate determination. Nature 416:854^860, 2002
Nishikawa S, Kusakabe M, Yoshinaga K, et al: In utero manipulation of coat
color formation by a monoclonal anti-c-kit antibody: two distinct waves
of c-kit-dependency during melanocyte development. EMBO J 10:2111^2118,
1991
Paus R, Cotsarelis G: The biology of hair follicles. New Engl J Med 341:491^497, 1999
Paus R, Handjiski B, Eichmuller S, Czarnetzki BM: Chemotherapy-induced alope-
cia in mice. Induction by cyclophosphamide, inhibition by cyclosporine A, and
modulation by dexamethasone. AmJ Pathol 144:719^734, 1994
Paus R, Muller-Rover S, Van Der Veen C, et al: A comprehensive guide for the re-
cognition and classi¢cation of distinct stages of hair follicle morphogenesis.
J Invest Dermatol 113:523^532, 1999
Paus R, Schilli MB, Handjiski B, Menrad A, Henz BM, Plonka P: Topical calcitriol
enhances normal hair regrowth but does not prevent chemotherapy-induced
alopecia in mice. Cancer Res 56:4438^4443, 1996
Pincelli C,Yaar M: Nerve growth factor: its signi¢cance in cutaneous biology. J Invest
Dermatol Symp ProcThe 2:31^36, 1997
Shindler KS, Roth KA: Double immuno£uorescent staining using two unconju-
gated primary antisera raised in the same species. J Histochem Cytochem
44:1331^1335, 1996
Slominski A, Paus R: Melanogenesis is coupled to murine anagen: toward new con-
cepts for the role of melanocytes and the regulation of melanogenesis in hair
growth. J Invest Dermatol 101:90S^97S, 1993
Slominski A, Paus R, Costantino R: Di¡erential expression and activity of melano-
genesis-related proteins during induced hair growth in mice. J Invest Dermatol
96:172^179, 1991
Slominski A, Paus R, Plonka P, ChakrabortyA, Maurer M, Pruski D, Lukiewicz S:
Melanogenesis during the anagencatagentelogen transformation of the
murine hair cycle. J Invest Dermatol 102:862^869, 1994
Slominski A, Paus R, Plonka P, Handjiski B, Maurer M, Chakraborty A, Mihm
MCJ: Pharmacological disruption of hair follicle pigmentation by cyclopho-
sphamide as a model for studying the melanocyte response to and recovery
from cytotoxic drug damage in situ. J Invest Dermatol 106:1203^1211, 1996
SomaT, Ogo M, Suzuki J,Takahashi T, HibinoT: Analysis of apoptotic cell death in
human hair follicles in vivo and in vitro. J Invest Dermatol 111:948^954, 1998
Song S, Lambert PF: Di¡erent responses of epidermal and hair follicle cells to radia-
tion correlate with distinct patterns of p53 and p21 induction. Am J Pathol
155:1121^1127, 1999
Stenn KS, Paus R: Control of hair follicle cycling. Physiol Rev 81:449^494, 2001
Susser WS,Whitaker-Worth DL, Grant-Kels JM: Mucocutaneous reactions to che-
motherapy. J Am Acad Dermatol 40:367^398, 1999
Tobin DJ, Hagen E, Botchkarev VA, Paus R: Do hair bulb melanocytes undergo
apoptosis during hair follicle regression (catagen)? J Invest Dermatol 111:941^
947, 1998
Tobin DJ, Slominski A, Botchkarev V, Paus R: The fate of hair follicle melano-
cytes during the hair growth cycle. J Invest Dermatol Symp ProcThe 4:323^332,
1999
Tsukamoto K, Jackson IJ, Urabe K, Montague P, Hearing VJ: A second tyrosinase-
related protein,TRP-2, is a melanogenic enzyme termed DOPAchrome tauto-
merase. EMBO J 11:519^526, 1992
Yoshida H, Kunisada T, Kusakabe M, Nishikawa S, Nishikawa SI: Distinct stages of
melanocyte di¡erentiation revealed by analysis of nonuniform pigmentation
patterns. Development 122:1207^1214, 1996
RESPONSE OF HAIR FOLLICLE MELANOCYTES TO CHEMOTHERAPY 35VOL. 120, NO. 1 JANUARY 2003
